 |
|
|
|
|
|
 |
|
Aspirin at the Royal Society of Medicine London: Recognition of Excellence
| |
The 5th annual Bayer HealthCare-sponsored International Experts Forum (IEF) was immensely successful, attracting nearly 200 delegates from almost 30 countries. The scientific programme was endorsed by both the Royal Society of Medicine (RSM) and the World Heart Federation (WHF), and delegates were awarded five continuing professional development credits by the Royal College of Physicians.
This year's IEF, held on Saturday 7 October at the RSM in London, UK, was opened by the Dean of the RSM, Professor Robin Williamson, and co-chaired by Professor Peter Elwood, Chairman of the Welsh Aspirin Group (UK), and Professor Sidney C. Smith, Jr, Chairman of the Scientific Advisory Board of the WHF (USA). The faculty comprised several of the world's leading specialists in molecular biology and cardio- and cerebrovascular medicine, and the delegates were clinicians and researchers in the fields of cardiology, neurology and diabetology.
Prevention is the key to reducing the global burden of cardio- and cerebrovascular diseases and, with this aim, Aspirin and other antiplatelet agents continue to be one of the most successful therapeutic strategies. A key objective of the forum was to review ongoing research into the molecular targets of Aspirin to determine whether further benefits may be conferred though its multiple mechanisms of action. The established role of Aspirin and wealth of data supporting the value of Aspirin in reducing the risks of cardio- and cerebrovascular diseases were also reviewed, including a preview of ongoing trials in primary prevention.
To explore the potential and established roles of Aspirin and inspire discussion, multiple meeting formats were employed, including expert presentations, audience Q&A, interactive patient profile sessions with panel-led audience discussions and a keypad voting system. This approach stimulated debate regarding the use of Aspirin therapy in individuals at varying levels of CV risk, particularly in those with diabetes in whom platelet aggregation is enhanced, and in the elderly, a group in which there is a clear need for a randomised, controlled trial of Aspirin.
| |
|
|
|
|
|
|
|
|
 |
|
 |
"After five years the external data monitoring board asked that we terminate the study because of a striking, very extreme benefit of aspirin. Aspirin® reduced the risk of a first heart attack by 44 percent, and this was quite an earthshaking finding at that time."
|
|
 |
|
|
Aspirin Cardio® Screensaver
Out now: The new Aspirin Cardio® Screensaver.
Download here...
|
|
 |
|
|
Aspirin Cardio® Trailer
Click here to download the Aspirin Cardio® Trailer "Did you know..."
|
|
|
|
|
|
|
|
|
